Literature DB >> 22389125

Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.

Guillermo J Pons-Estel1, Graciela S Alarcón, Leticia Hachuel, Gabriela Boggio, Daniel Wojdyla, Virginia Pascual-Ramos, Enrique R Soriano, Verónica Saurit, Fernando S Cavalcanti, Renato A Guzman, Marlene Guibert-Toledano, Maria J Sauza Del Pozo, Mary-Carmen Amigo, Magaly Alva, Maria H Esteva-Spinetti, Bernardo A Pons-Estel.   

Abstract

OBJECTIVE: To examine the role of ethnicity and the use of anti-malarials (protective) on lupus renal disease.
METHODS: A nested case-control study (1:2 proportion, n = 265 and 530) within GLADEL's (Grupo Latino Americano De Estudio de Lupus) longitudinal inception cohort was carried out. The end-point was ACR renal criterion development after diagnosis. Cases and controls were matched for follow-up time (end-point or a comparable time, respectively). Renal disease predictors were examined by univariable and multivariable analyses. Additional analyses were done to determine if the protective effect of anti-malarials persisted after adjusting for intake-associated confounders.
RESULTS: Of the cases, 233 (87.9%) were women; their mean (s.d.) age at diagnosis was 28.0 (11.9) years and their median (Q3-Q1 interquartile range) follow-up time for cases and controls was 8.3 months (Q3-Q1: 23.5); 56.6% of the cases and 74.3% of the controls were anti-malarial users. Mestizo ethnicity [odds ratio (OR) 1.72, 95% CI 1.19, 2.48] and hypertension (OR 2.26, 95% CI 1.38, 3.70) were independently associated with a higher risk of renal disease, whereas anti-malarial use (OR 0.39, 95% CI 0.26, 0.58), older age at disease onset (OR 0.98, 95% CI 0.96, 0.99) and female gender (OR 0.56, 95% CI 0.32, 0.99) were negatively associated with such occurrence. After adjusting for variables associated with their intake, the protective effect of anti-malarials on renal disease occurrence persisted (OR 0.38, 95% CI 0.25, 0.58).
CONCLUSION: Mestizo patients are at increased risk of developing renal disease, whereas anti-malarial use protects patients from such an occurrence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389125      PMCID: PMC3380245          DOI: 10.1093/rheumatology/ker514

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

Review 1.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

2.  Outcomes in African Americans and Hispanics with lupus nephritis.

Authors:  G Contreras; O Lenz; V Pardo; E Borja; C Cely; K Iqbal; N Nahar; C de La Cuesta; A Hurtado; A Fornoni; L Beltran-Garcia; A Asif; L Young; J Diego; M Zachariah; B Smith-Norwood
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

3.  Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes.

Authors:  C-H Jang; J-H Choi; M-S Byun; D-M Jue
Journal:  Rheumatology (Oxford)       Date:  2006-01-17       Impact factor: 7.580

4.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

5.  Baseline characteristics of a multiethnic lupus cohort: PROFILE.

Authors:  G S Alarcón; G McGwin; M Petri; J D Reveille; R Ramsey-Goldman; R P Kimberly
Journal:  Lupus       Date:  2002       Impact factor: 2.911

6.  Sustained remission of lupus nephritis.

Authors:  C E H Barber; L Geldenhuys; J G Hanly
Journal:  Lupus       Date:  2006       Impact factor: 2.911

7.  Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement.

Authors:  G S Alarcón; H M Bastian; T M Beasley; J M Roseman; F K Tan; B J Fessler; L M Vilá; G McGwin
Journal:  Lupus       Date:  2006       Impact factor: 2.911

8.  The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics".

Authors:  Bernardo A Pons-Estel; Luis J Catoggio; Mario H Cardiel; Enrique R Soriano; Silvana Gentiletti; Antonio R Villa; Isaac Abadi; Francisco Caeiro; Alejandro Alvarellos; Donato Alarcón-Segovia
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

Review 10.  Hydroxychloroquine: from malaria to autoimmunity.

Authors:  Ilan Ben-Zvi; Shaye Kivity; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

View more
  13 in total

Review 1.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

2.  Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America.

Authors:  Juliana C O A Ferreira; Vitor C Trindade; Graciela Espada; Zoilo Morel; Eloisa Bonfá; Claudia S Magalhães; Clovis Artur Silva
Journal:  Clin Rheumatol       Date:  2018-08-09       Impact factor: 2.980

3.  Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort.

Authors:  G J Pons-Estel; G S Alarcón; P I Burgos; L Hachuel; G Boggio; D Wojdyla; R Nieto; A Alvarellos; L J Catoggio; M Guibert-Toledano; J Sarano; L Massardo; G M Vásquez; A Iglesias-Gamarra; L T Lavras Costallat; N A Da Silva; J L Alfaro; I Abadi; M I Segami; G Huerta; M H Cardiel; B A Pons-Estel
Journal:  Lupus       Date:  2013-07-15       Impact factor: 2.911

4.  Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study.

Authors:  M Scolnik; J Marin; S M Valeiras; M F Marchese; A S Talani; N L Avellaneda; A Etchepare; P Etchepare; M S Plou; E R Soriano
Journal:  Lupus Sci Med       Date:  2014-06-05

5.  Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina.

Authors:  Rosana Quintana; Adriana M R Silvestre; Mario Goñi; Vanina García; Nora Mathern; Marisa Jorfen; Julio Miljevic; Daniel Dhair; Matias Laithe; Silvana Conti; Fadua Midauar; Maria Celeste Martin; Maria Cecilia Barrios; Romina Nieto; Cristina Prigione; Alvaro Sanabria; Viviana Gervasoni; Emilio Grabbe; Romina Gontero; Ingris Peláez-Ballestas; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

6.  Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.

Authors:  Maria Victoria Collado; Enrique Dorado; Silvia Rausch; Graciela Gomez; Marina Khoury; Federico Zazzetti; María Gargiulo; Lorena Suarez; Rafael Chaparro; Sergio Paira; Laura Galvan; Vicente Juarez; Cecilia Pisoni; Mercedes Garcia; Liliana Martinez; Analia Alvarez; Clarisa Alvarez; Juan Barreira; Judith Sarano
Journal:  J Clin Rheumatol       Date:  2016-09       Impact factor: 3.517

7.  Predictors of incident proteinuria among patients with SLE.

Authors:  Alí Duarte-García; Erik Barr; Laurence S Magder; Michelle Petri
Journal:  Lupus Sci Med       Date:  2017-05-22

Review 8.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

9.  Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER).

Authors:  María Galindo-Izquierdo; Esther Rodriguez-Almaraz; José M Pego-Reigosa; Francisco J López-Longo; Jaime Calvo-Alén; Alejandro Olivé; Antonio Fernández-Nebro; Víctor Martinez-Taboada; Paloma Vela-Casasempere; Mercedes Freire; Francisco J Narváez; José Rosas; Mónica Ibáñez-Barceló; Esther Uriarte; Eva Tomero; Antonio Zea; Loreto Horcada; Vicenç Torrente; Iván Castellvi; Joan Calvet; Raúl Menor-Almagro; María A Aguirre Zamorano; Enrique Raya; Elvira Díez-Álvarez; Tomás Vázquez-Rodríguez; Paloma García de la Peña; Atusa Movasat; José L Andreu; Patricia Richi; Carlos Marras; Carlos Montilla-Morales; Blanca Hernández-Cruz; José L Marenco de la Fuente; María Gantes; Eduardo Úcar; Juan J Alegre-Sancho; Javier Manero; Jesús Ibáñez-Ruán; Manuel Rodríguez-Gómez; Víctor Quevedo; José Hernández-Beriaín; Lucía Silva-Fernández; Fernando Alonso; Sabina Pérez; Iñigo Rúa-Figueroa
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Authors:  Bernardo A Pons-Estel; Eloisa Bonfa; Enrique R Soriano; Mario H Cardiel; Ariel Izcovich; Federico Popoff; Juan M Criniti; Gloria Vásquez; Loreto Massardo; Margarita Duarte; Leonor A Barile-Fabris; Mercedes A García; Mary-Carmen Amigo; Graciela Espada; Luis J Catoggio; Emilia Inoue Sato; Roger A Levy; Eduardo M Acevedo Vásquez; Rosa Chacón-Díaz; Claudio M Galarza-Maldonado; Antonio J Iglesias Gamarra; José Fernando Molina; Oscar Neira; Clóvis A Silva; Andrea Vargas Peña; José A Gómez-Puerta; Marina Scolnik; Guillermo J Pons-Estel; Michelle R Ugolini-Lopes; Verónica Savio; Cristina Drenkard; Alejandro J Alvarellos; Manuel F Ugarte-Gil; Alejandra Babini; André Cavalcanti; Fernanda Athayde Cardoso Linhares; Maria Jezabel Haye Salinas; Yurilis J Fuentes-Silva; Ana Carolina Montandon de Oliveira E Silva; Ruth M Eraso Garnica; Sebastián Herrera Uribe; Diana Gómez-Martín; Ricardo Robaina Sevrini; Rosana M Quintana; Sergio Gordon; Hilda Fragoso-Loyo; Violeta Rosario; Verónica Saurit; Simone Appenzeller; Edgard Torres Dos Reis Neto; Jorge Cieza; Luis A González Naranjo; Yelitza C González Bello; María Victoria Collado; Judith Sarano; Soledad Retamozo; María E Sattler; Rocio V Gamboa-Cárdenas; Ernesto Cairoli; Silvana M Conti; Luis M Amezcua-Guerra; Luis H Silveira; Eduardo F Borba; Mariana A Pera; Paula B Alba Moreyra; Valeria Arturi; Guillermo A Berbotto; Cristian Gerling; Carla A Gobbi; Viviana L Gervasoni; Hugo R Scherbarth; João C Tavares Brenol; Fernando Cavalcanti; Lilian T Lavras Costallat; Nilzio A Da Silva; Odirlei A Monticielo; Luciana Parente Costa Seguro; Ricardo M Xavier; Carolina Llanos; Rubén A Montúfar Guardado; Ignacio Garcia de la Torre; Carlos Pineda; Margarita Portela Hernández; Alvaro Danza; Marlene Guibert-Toledano; Gil Llerena Reyes; Maria Isabel Acosta Colman; Alicia M Aquino; Claudia S Mora-Trujillo; Roberto Muñoz-Louis; Ignacio García Valladares; María Celeste Orozco; Paula I Burgos; Graciela V Betancur; Graciela S Alarcón
Journal:  Ann Rheum Dis       Date:  2018-07-25       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.